Today's edition · Friday, November 20, 2026
Every story verifiedNo politics. Ever.No pop-ups
TodayLocalWorldHeroesAnimalsScienceCommunityHealth & TechMapQuizKindnessAnnouncementsKidsTopicsExplainersOn this dayCalendarGood NeighborHometown Heroes

TodayHealth & TechMaryland

Health & TechSilver Spring, Maryland

FDA approves Livsayis, a four-times-a-year shot for myasthenia gravis

Livsayis is the first siRNA drug for anti-AChR-positive generalized myasthenia gravis. In a 24-week trial, 77 percent of adults improved on daily-living scores, compared with 44 percent on placebo. It carries a meningococcal infection warning.

Verified · Source: WebMDNov 19, 2026 · 1 min read
How to help
The glass and metal exterior of an FDA office building
Photo of an FDA building. It does not show Livsayis, a patient, or a clinic. U.S. Food and Drug Administration / Wikimedia Commons · Public domain

Read the original

The reporting lives at WebMD. Our summary is checked against it, and we link it on every story.

The FDA approved Livsayis, a shot given four times a year, for adults with anti-AChR-positive generalized myasthenia gravis, WebMD reported. It is the first siRNA drug for that form of the disease. In a 24-week trial of 123 adults, 77 percent of people on Livsayis improved meaningfully on daily-living scores, compared with 44 percent on placebo.

The approval comes with a warning about meningococcal infection, and vaccination is required. The 123 adults are the trial group. Seventy-seven percent and 44 percent are the shares who improved on those scores. This is an approval based on that trial, not a claim that every patient will see the same result.

More good news

Other stories in the same neighborhood of kindness.